European cell counting market was valued at $512.7 million in 2025 and is projected to reach $905.4 million by 2035, growing at a CAGR of 5.9% during the forecast period (2026–2035). Rising healthcare investment across Europe is strengthening diagnostic infrastructure and accelerating demand for cell counting services, particularly in oncology and pathology. Increased funding is enabling the adoption of scalable laboratory models that improve turnaround times, standardization, and access to high-quality diagnostics across national healthcare systems. Major diagnostic service providers are actively expanding their footprints across Europe through cross-border laboratory setups, acquisitions, and capacity expansion to address growing test volumes.
Browse the full report description of “European Cell Counting Market Size, Share & Trends Analysis Report by Product Type (Instruments and Consumables), By Application (Medical Applications, Research, and Industrial), By End-User (Pharmaceuticals & Biotechnology Companies, Research Institutes & CRO, and Hospitals & Diagnostic Laboratories), Forecast Period 2026-2035” of https://www.omrglobal.com/industry-reports/europe-cell-counting-market
For instance, in October 2023, Inify Laboratories has announced plans to establish operations in the United Kingdom following its successful launch in Sweden, where it has achieved approximately 80% market share in the Stockholm region and supports around 10% of all prostate cancer diagnostics nationwide. The UK market, estimated to be six times larger than Sweden with approximately 120,000 patients annually, offers significant growth potential amid long turnaround times and variable diagnostic quality. To support this expansion, Inify plans to raise approximately SEK 150 million through a share issue. UK laboratory operations are expected to begin clinical activities in early 2026, initially supported by sample processing in Sweden. In parallel, the company is expanding into gastrointestinal diagnostics, a segment with sample volumes nearly ten times larger than prostate diagnostics, strengthening its high-throughput laboratory model.
Rising private equity investment is also reshaping Central Europe’s diagnostic infrastructure through consolidation and long-term platform development. MidEuropa’s partnership with Diagnostyka demonstrates sustained capital commitment to developing scaled, nationally integrated healthcare service providers across the region. Since its investment in 2011, MidEuropa has supported Diagnostyka’s growth through 128 acquisitions, greenfield developments, and major infrastructure upgrades. This strategy has driven more than a fifteen fold increase in revenues while significantly expanding operational scale. Diagnostyka now operates over 1,100 blood collection points and 156 diagnostic laboratories. The company serves approximately 20 million patients annually and conducts more than 140 million diagnostic tests each year. Its scale and network position it as a key provider of high-volume diagnostics, including cell counting services, supporting improved access and efficiency across Central European healthcare systems.
Major Players Innovate and Expand in European Cell Counting Market
The major companies operating in the European cell counting market include Abbott Laboratories, Becton, Dickinson and Company, Roche Diagnostics International Ltd., and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Market Coverage
Key questions addressed by the report.
European Cell Counting Market Report Segment
By Product Type
By Application
By End-User
European Cell Counting Market Report Segment by Region
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-cell-counting-market